Guangdong Biolight Meditech Launches Patient Monitors with Masimo Rainbow SET Pulse CO-Oximetry
10/24/2011 -- IRVINE, Calif. and ZHUHAI, China, Oct. 24, 2011 /PRNewswire/ -- Masimo (NASDAQ: MASI) and Biolight, a leading global manufacturer of electronic medical devices and patient monitors, jointly announced both a worldwide technology licensing agreement and the launch of Masimo rainbow® SET Pulse CO-Oximetry technology in Biolight's new generation of modular patient monitors. The agreement allows Biolight to incorporate the breakthrough noninvasive blood constituent measurement capabilities of Masimo rainbow SET into Biolight's Anyview Series of modular monitors and the Measure-Through Motion and Low Perfusion pulse oximetry capabilities of Masimo SET across Biolight's product line of multiparameter patient monitors - facilitating early detection and treatment of life-threatening conditions.
According to James Yan, Chairman General Manager, Professor Senior Engineering, R&D. "Our corporate mission is to provide innovative medical devices with superior performance and value. The integration of Masimo rainbow SET Pulse CO-Oximetry and Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry technologies is an example of our mission in action. Masimo's innovative technologies and breakthrough noninvasive monitoring solutions provide clinicians with the ability to more rapidly and thoroughly assess a patient's physiological status and make better clinical and treatment decisions."
Integrating Masimo rainbow SET Pulse CO-Oximetry technology into Biolight's Anyview Series of modular monitors will provide immediate and continuous access to additional clinical measurement data - enabling clinicians to detect and treat the early signs of hemodynamic instability, internal bleeding, and respiratory distress sooner. Masimo rainbow SET Pulse CO-Oximetry is a breakthrough technology platform revolutionizing patient monitoring by significantly expanding the ability to noninvasively measure and continuously track multiple blood constituents that previously required intermittent, invasive procedures, including: total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and perfusion index (PI), in addition to the 'gold standard' Measure-Through Motion and Low Perfusion performance of Masimo SET® oxyhemoglobin (SpO2), and pulse rate (PR).
"The inclusion of Masimo technologies will allow us to optimize the design and manufacture of state-of-the-art patient monitors and provide our domestic and international customers with access to the latest in cutting-edge, noninvasive physiological measurements," continued Yan. "As one of the first medical device manufacturers in China to incorporate Masimo's rainbow SET technology, we expect our combined product offering will allow clinicians to advance the delivery of healthcare across all patient care settings."
Incorporating Masimo's core Signal Extraction Technology (SET) pulse Oximetry technology into Biolight's non-modular "M" and "V" Series of patient monitors will also help clinicians more accurately measure a patient's oxygenation during challenging conditions such as patient motion and low perfusion to facilitate better treatment decisions – as clinically proven in over 100 independent studies. Utilizing patented signal processing technologies, including parallel engines and adaptive filters, Masimo SET delivers accurate and reliable measurements of a patient's true oxygenation status when conventional pulse oximetry technologies don't—reducing false alarms by over 95% (sensitivity) and expanding true alarm detection to over 97% (specificity).(1)
Rick Fishel, President of Worldwide OEM Business and Corporate Development at Masimo, stated, "Biolight is one of the first patient monitoring manufacturers in China to integrate Masimo rainbow SET Pulse CO-Oximetry technology. This "first-to-market" commitment in Biolight's modular Anyview series of patient monitors provides Biolight customers with advanced physiological monitoring across a broad range of monitors which offer a unique combination of upgradeability and point-of-care flexibility."
1 Shah N., Estanol L. "An Evaluation of Three New Generation Pulse Oximeters during Motion & Low Perfusion in Volunteers." Anesthesiology 2006; 102: S-75.
To see a summary of all known clinical studies and abstracts on Masimo technologies, please visit: http://www.masimo.com/cpub/clinicals.htm.